Top

International Journal of Clinical Oncology

Published in:

01-04-2015 | Original Article

[¹⁸F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma

Authors: Hiroyuki Shimomura, Tomonori Sasahira, Yasutsugu Yamanaka, Miyako Kurihara, Yuichiro Imai, Shigehiro Tamaki, Nobuhiro Yamakawa, Norihisa Shirone, Masatoshi Hasegawa, Hiroki Kuniyasu, Tadaaki Kirita

Published in: International Journal of Clinical Oncology | Issue 2/2015

Abstract

Background

[¹⁸F]fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) is widely used to evaluate tumor metabolic activity. The aim of this study was to evaluate the usefulness of FDG-PET in assessing the histopathological response to preoperative concurrent chemoradiotherapy (CRT) in patients with oral squamous cell carcinoma (OSCC).

Methods

Forty-five patients with resectable advanced OSCC who had received preoperative CRT followed by tumor ablative surgery between January 2004 and December 2011 were included in the study. All patients underwent FDG-PET before and after preoperative CRT. The maximum standardized uptake value (SUVmax) before (pre-SUV) and after preoperative CRT (post-SUV) and the SUVmax reduction rate (ΔSUV %) were used to evaluate the response to preoperative CRT. Correlations among SUVmax, histopathological response, and expression of cancer antigen Ki-67 and hypoxia-inducible factor-1α (HIF-1α) were analyzed.

Results

Preoperative CRT significantly reduced intratumoral FDG uptake (P < 0.001). The pre-SUV and post-SUV were significantly lower in patients with a pathological complete response (pCR) than in those with a non-pCR (pre-SUV P = 0.037; post-SUV P = 0.001). ΔSUV % was higher in patients with pCR than in those with non-pCR (P = 0.029). The pre-SUV was significantly correlated with Ki-67 and HIF-1α expression in pretreatment biopsy specimens (Ki-67 P = 0.046, R = 0.292; HIF-1α P = 0.007, R = 0.385). The expression of both Ki-67 and HIF-1α was significantly lower in patients with pCR than in those with non-pCR (Ki-67 P < 0.001; HIF-1α P < 0.001).

Conclusions

Low pre-SUV and post-SUV and high ΔSUV % may predict a good histopathological response to preoperative CRT. Ki-67 and HIF-1α expression in pretreatment biopsy specimens were predictors of histopathological response to preoperative CRT.

Japan Society for Head and Neck Cancer Cancer Registry Committee (2006) Report of head and neck cancer registry of Japan clinical statistics of registered patients, 2002. Jpn J Head Neck Cancer 32:1–98

Izumo T, Kirita T, Ariji E et al (2012) General rules for clinical and pathological studies on oral cancer: a synopsis. Jpn J Clin Oncol 42:1099–1109CrossRefPubMed

Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of chemotherapy on head and neck cancer. Lancet 355:949–955CrossRefPubMed

Kirita T, Ohgi K, Shimooka H et al (1999) Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity: an analysis of long-term results. Oral Oncol 35:597–606CrossRefPubMed

Yamanaka Y, Tamaki S, Shimomura H et al (2011) A case of advanced upper gingival carcinoma responding completely to concurrent chemoradiotherapy with S-1. Gan To Kagaku Ryoho 38:89–92 (in Japanese)PubMed

Klug C, Berzaczy D, Voracek M et al (2008) Preoperative chemoradiotherapy in the management of oral cancer: a review. J Craniomaxillofac Surg 36:75–88CrossRefPubMed

Eckardt A, Sinikovic B, Hofele C et al (2007) Preoperative paclitaxel/carboplatin radiochemotherapy for stage III/IV resectable oral and oropharyngeal cancer: seven-year follow-up of a phase II trial. Oncology 73:198–203CrossRefPubMed

Kirita T, Yamanaka Y, Imai Y et al (2012) Preoperative concurrent chemoradiotherapy for stages II-IV oral squamous cell carcinoma: a retrospective analysis and the future possibility of this treatment strategy. Int J Oral Maxillofac Surg 41:421–428CrossRefPubMed

Kitagawa Y, Sano K, Nishizawa S et al (2003) FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging 30:63–71CrossRefPubMed

10.

Lee SW, Nam SY, Im KC et al (2008) Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 87:211–216CrossRefPubMed

11.

Kim MK, Ryu JS, Kim SB et al (2007) Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43:1385–1391CrossRefPubMed

12.

Higashi K, Ueda Y, Arisaka Y et al (2002) 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 43:39–45PubMed

13.

Shimosato Y, Obishi S, Baba K (1971) Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol 1:19–35

14.

Sasahira T, Ueda N, Yamamoto K et al (2013) Trks are novel oncogenes involved in the induction of neovascularization, tumor progression, and nodal metastasis in oral squamous cell carcinoma. Clin Exp Metastasis 30:165–176CrossRefPubMed

15.

Ishihara R, Yamamoto S, Iishi H et al (2012) Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy. Int J Clin Oncol 17:225–232CrossRefPubMed

16.

Kresnik E, Mikosch P, Gallowitsch HJ et al (2001) Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med 28:816–821CrossRef

17.

Kim SY, Kim JS, Doo H et al (2011) Combined [18F] fluorodeoxyglucose positron emission tomography and computed tomography for detecting contralateral neck metastases in patients with head and neck squamous cell carcinoma. Oral Oncol 47:376–380CrossRefPubMed

18.

Vaupel P, Thews O, Hoeckel M (2001) Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18:243–259CrossRefPubMed

19.

Nguyen XC, Lee WW, Chung JH et al (2007) FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 62:214–219CrossRefPubMed

20.

Jalava P, Kuopio T, Juntti-Patinen L et al (2006) Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48:674–682CrossRefPubMed

21.

Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569–5575CrossRefPubMedCentralPubMed

22.

Pugsley JM, Schmidt RA, Vesselle H (2002) The Ki-67 index and survival in non-small cell lung cancer: a review and relevance to positron emission tomography. Cancer J 8:222–233CrossRefPubMed

23.

Harada H, Kizaka-Kondoh S, Li G et al (2007) Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 26:7508–7516CrossRefPubMed

24.

Song X, Liu X, Chi W et al (2006) Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 58:776–784CrossRefPubMed

25.

García Vicente AM, Castrejón ÁS, Relea Calatayud F et al (2012) 18F-FDG retention index and biologic prognostic parameters in breast cancer. Clin Nucl Med 37:460–466CrossRefPubMed

26.

Yamada T, Uchida M, Kwang-Lee K et al (2012) Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol 113:464–471CrossRefPubMed

27.

Oshida M, Uno K, Suzuki M et al (1998) Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-d-glucose. Cancer 82:2227–2234CrossRefPubMed

28.

Vansteenkiste JF, Stroobants SG, Dupont PJ et al (1999) Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17:3201–3206PubMed

29.

Brun E, Kjellén E, Tennvall J et al (2002) FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24:127–135CrossRefPubMed

30.

Vallbohmer D, Holscher AH, Dietlein M et al (2009) [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 250:888–894CrossRefPubMed

31.

Miyawaki A, Ikeda R, Hijioka H et al (2010) SUVmax of FDG-PET correlates with the effects of neoadjuvant chemoradiotherapy for oral squamous cell carcinoma. Oncol Rep 23:1205–1212CrossRefPubMed

32.

Jingu K, Kaneta T, Nemoto K et al (2010) (18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer. Int J Clin Oncol 15:184–190CrossRefPubMed

Title: [18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma
Authors: Hiroyuki Shimomura
Tomonori Sasahira
Yasutsugu Yamanaka
Miyako Kurihara
Yuichiro Imai
Shigehiro Tamaki
Nobuhiro Yamakawa
Norihisa Shirone
Masatoshi Hasegawa
Hiroki Kuniyasu
Tadaaki Kirita
Publication date: 01-04-2015
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-014-0711-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2015

Disease control and clinicopathological prognostic factors of total pharyngolaryngectomy for hypopharyngeal cancer: a single-center study

Comparison of diameter-axial-polar nephrometry and RENAL nephrometry score for treatment decision-making in patients with small renal mass

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis

Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor

Keynote webinar | Spotlight on antibody–drug conjugates in cancer